Which antibiotic is commonly used in ARE as part of a short trial to modulate gut flora and inflammation?

• A. Clindamycin
• B. Azithromycin
• C. Doxycycline
• D. Tylosin

Answer: (D)

In antibiotic-responsive enteropathy (ARE), a short, gut-targeted antibiotic trial is used to see if modulation of the intestinal microbiota reduces inflammation and clinical signs. Tylosin fits best here because it is a macrolide with strong activity in the gut lumen and relatively low systemic absorption, plus it has been shown to help many dogs with ARE by altering the gut bacterial population and providing anti-inflammatory effects in the intestine. A typical approach is a brief course (often a couple of weeks) to observe whether there is an improvement in stool quality, frequency, and overall signs; if there’s a positive response, it supports the role of dysbiosis in the disease and guides ongoing management. The other antibiotics listed are not the standard short, gut-focused ARE trial because they either act more systemically or don’t have the same track record for improving ARE-related inflammation, so they’re less likely to be used for this specific purpose.